Complex Biomolecules Require Analytical Evolution

Publication
Article
BioPharm InternationalBioPharm International, 2021 Biopharmaceutical Analysis eBook
Volume 2021 eBook
Issue 3
Pages: 4–8

The ever-increasing complexity of biotherapeutic molecules presents unique analytical challenges for developers.

Kateryna_Kon/Stock.adobe.com – complex biomolecules pose unique challenges for drug developers seeing analytical characterization.

Kateryna_Kon/Stock.adobe.com

The structure and activity of complex biotherapeutic molecules require sensitive analytical technologies that can characterize these complicated protein structures and observe their pharmacokinetic activity, elements fundamental to biotherapeutic drug development and production. Relevant technologies are needed to make detailed analytical assessments of structure, function, and purity, and further innovation is needed to address the continued challenge faced by the industry, including approaches to analytical method development and multiple analytical assays.

Read this article in BioPharm International’s July 2021 Biopharmaceutical Analysis eBook.

About the author

Feliza Mirasol is the science editor for BioPharm International.

Article Details

BioPharm International
eBook: Biopharmaceutical Analysis, July 2021
July 2021
Pages: 4–8

Citation

When referring to this article, please cite it as F. Mirasol, “Complex Biomolecules Require Analytical Evolution," BioPharm International Biopharmaceutical Analysis eBook (July 2021).

Articles in this issue
Kateryna_Kon/Stock.adobe.com – complex biomolecules pose unique challenges for drug developers seeing analytical characterization.
Complex Biomolecules Require Analytical Evolution
tilialucida/Stock.adobe.com – bioanalytical method development is important to establish early on in the drug development life cycle.
Best Practices for Analytical Method Validation: Study Design, Analysis, and Acceptance Criteria
Data Integrity Associated with Analytical Testing
Data Integrity Considerations for Vendor-Generated Data Associated with Analytical Testing
Detecting Residual HCPs Demands a Holistic Approach; image: eplisterra - Stock.adobe.com
Detecting Residual HCPs Demands a Holistic Approach
HCP Analysis with TIMS-MS
Increasing the Depth and Reliability of HCP Analysis Using TIMS-MS
Robert Kneschke/stock.adobe.com – MMS is a recent innovation that can help improve analysis of secondary protein structure.
Improving IR Spectroscopy as a Tool for Biopharmaceutical Analysis
Prioritizing Cleaning Validation; bankrx - Stock.adobe.com
Prioritizing Cleaning Validation

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!
Recent Videos
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
DC skyline at night with view of the White House and the Washington Monument | Image Credit: © Jessica - stock.adobe.com
Related Content
Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Pfizer Obtains Exclusive Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF

Susan Haigney
July 25th 2025
Article

The licensing agreement between the two companies gives Pfizer the rights to develop, manufacture, and commercialize 3SBio’s bispecific antibody, SSGJ-707, which is in clinical trials for the treatment of a variety of cancers.

Podcast: Alternative Drug Delivery Methods for Biologics: Where Are We At?

Podcast: Alternative Drug Delivery Methods for Biologics: Where Are We At?

Feliza Mirasol
September 27th 2024
Podcast

This podcast explores the challenges of and the progress made so far by the biopharma industry toward alternative drug delivering methods for biologic drugs.

Cancer Question | Image Credit: ©freshidea - Stock.adobe.com

ICH Q12 and Post-Approval Changes–Less than Satisfactory State of Affairs

Siegfried Schmitt
July 25th 2025
Article

Speedier implementation of the Post-Approval Change Management Protocol is essential for it to have a positive effect on supply security, says Siegfried Schmitt, PhD, vice president, Technical at Parexel.

Drug Solutions Podcast: Considering Biologic Drug Development and Manufacturing Holistically

Drug Solutions Podcast: Considering Biologic Drug Development and Manufacturing Holistically

Felicity Thomas
May 25th 2023
Podcast

Hanns-Christian Mahler and Andrea Allmendinger from ten23 health will discuss some key aspects of biologic drug development and manufacturing.

Pharmaceutical Optical Ampoule / Vial Inspection Machine. 3d illustration | Image Credit: © unlimit3d - stock.adobe.com

Potential Effects of MHRA’s New Decentralized Manufacture Regulations

Patrick Lavery
July 23rd 2025
Article

Manufacturing sites and a control site will work together in a hub-and-spoke model that has key differences from conventional manufacturing operations.

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

FDA Extends Review Period for GSK’s Blenrep

Susan Haigney
July 23rd 2025
Article

The agency has extended the review period for GSK’s biologics license application for belantamab mafodotin-blmf for the treatment of relapsed/refractory multiple myeloma.

© 2025 MJH Life Sciences

All rights reserved.